IGI Logo

Specialized BPO players taking the lead

* The BPO landscape is increasingly bifurcating between sector-focused vs domain-led providers and broad-based IT services companies with BPO/BPM capabilities. Notably, this distinction has become more relevant in the AI era, as clients increasingly seek not just cost savings but domain expertise, workflow transformation, and measurable business outcomes.

* Niche, specialized, innovative, and sizable healthcare and life science-focused BPO/KPO players, such as Inventurus Knowledge Solutions (IKS), Sagility, and Indegene, are expected to witness reasonable business momentum, driven by consolidation among peers and increasing outsourcing of operational, clinical, regulatory, and analytics functions by healthcare payers, providers, pharmaceuticals, and biotech firms to specialized service providers.

* Strong growth outlook with FY27 normalization: IKS, Sagility, and Indegene delivered a healthy 1QFY27 performance, driven by sustained client demand and deals. Management remains constructive, with IKS expecting organic growth to outperform the ~12% industry growth rate, Sagility guiding for low double-digit organic CC growth and a 24–25% adjusted EBITDA margin, and Indegene expecting FY27 performance to improve over FY26.

* Margins broadly resilient; near-term pressures manageable: Sagility’s EBITDA margin of 22.3% was broadly in line, while IKS at ~33.0% and Indegene at 16.4% were marginally below our estimates; however, margins are expected to improve from 2HFY27.

1QFY27 earnings key highlights

1) IKS

Performance and guidance

* USD revenue stood at USD97m, rising 12% YoY, while INR revenue stood at INR8.9b, rising 21% YoY, led by top clients.

* Management expects organic business to outperform the industry’s outsourcing growth rate (~12%).

* Focus remains on building proprietary healthcare AI capabilities. Through Trubridge, IKS now has access to more than 5m patient records, which will be de-identified and used to train proprietary small language models (SLMs).

2) Sagility

Performance and guidance

* Sagility delivered a strong start to FY27, with revenue of INR19.6b (USD207.8m), rising 27.6% YoY (15.2% CC), while organic revenue grew 27.3% YoY (14.9% CC).

* Management retained its guidance of low double-digit organic CC growth for FY27.

* It remains confident of sustaining its FY27 EBITDA margin guidance of 24–25% through operational efficiencies, productivity initiatives, expansion into lowercost delivery centers, and favorable forex.

* Growth continues to be driven entirely by volumes rather than pricing, supported by deeper penetration within existing clients, increasing demand for higher-value clinical, and care management services

3) Indegene

Performance and guidance

* In 1Q, USD revenue stood at USD113m, growing 26.5% YoY and 2.5% QoQ, while INR revenue grew INR10.6b, rising 39.7% YoY and 6.0% QoQ. Notably, growth was broad-based across clients, geographies, and service lines.

* EBITDA margin expanded 10bp QoQ to 16.4%, and EBIT margin stood at 12.2%. Margins are expected to improve in 2H amid higher volume of business and normalization of D&A.

* Revenue productivity improved, with trailing revenue per employee at ~USD77k, rising ~25% over the past two years.

* The company expects FY27 organic growth to be better than FY26.

4) eClerx Services

Performance and guidance

* In 1Q, USD revenue stood at USD126m, growing 15.2% YoY and 2.8% QoQ, while INR revenue increased INR11.5b, rising 23.3% YoY and 4.1% QoQ. CC revenue growth stood at 2.9% QoQ and 15.0% YoY.

* EBITDA margin stood at 24.2%, declining 330bp QoQ, mainly due to the wage hike impact (210bp) and maintenance costs (~40bp).

* The company expects QoQ growth to continue, with EBITDA margin remaining around the midpoint of 24-28% range in FY27.

5) Firstsource Solutions

Performance and guidance

* In 1Q, USD revenue stood at USD288m, growing 11.2% YoY and 1.8% QoQ, while INR revenue increased to INR27.2b, rising 22.9% YoY and 5.5% QoQ. CC revenue growth stood at 2.2% QoQ and 12.3% YoY.

* EBITDA margin stood at 16.6%, declining 10bp QoQ and rising 90bp YoY.

* For FY27, the company is expected to post 10-13% CC revenue growth and EBIT margin of 12.3-12.8%, expecting 2H to be stronger as 1Q deal wins ramp over the next three months.

For More Research Reports : Click Here 

For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412